<DOC>
	<DOCNO>NCT00672165</DOCNO>
	<brief_summary>The purpose study find safe dose actinium-225 label HuM195 . This do `` phase I trial , '' preset schedule dose get powerful new group patient trial progress . If many serious side effect see certain dose , one treat high dose , additional patient may treat low dose make sure dose safe . The start dose actinium-225 study less dos know safe animal . Antibodies proteins produce immune system help body fight foreign substance , bacteria virus . HuM195 make put human leukemia cell mice . Most mouse part antibody replace human part . Only part antibody bind leukemia cell keep mouse . HuM195 attach leukemia cell attach normal cell . It kill small amount disease identify leukemia cell `` foreign . '' HuM195 work less well large amount leukemia since normal immune cell need kill leukemia cell lower patient leukemia .</brief_summary>
	<brief_title>Targeted Atomic Nano-Generators ( Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195 ) Patients With Advanced Myeloid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must one follow pathologically confirm diagnosis : AML relapse , AML refractory least 2 course standard induction chemotherapy one course highdose cytarabinecontaining induction chemotherapy , CML accelerate phase myeloid blast crisis progress treatment imatinib second generation tyrosine kinase inhibitor ( e.g. , dasatinib nilotinib ) RAEB International Prognostic Scoring System ( IPSS ) score ≥ 2.5 , CMMOL IPSS score ≥ 2.5 refractory relapse hypomethylating agent ( e.g. , azacitidine decitabine ) refractory relapse hypomethylating agent ( e.g. , azacitidine decitabine ) . Greater 25 % bone marrow blast must CD33 positive . Patients must life expectancy least 6 week Karnofsky performance status ≥ 60 % . Adequate renal function demonstrate serum creatinine ≤ 1.5 mg/dl , creatinine clearance &gt; 60 ml/min , &lt; 1 gram urinary protein/24 hour . Adequate hepatic function demonstrate bilirubin ≤ 1.5 mg/dl ( unless attributable leukemia Gilbert 's disease ) alkaline phosphatase AST ≤ 2.5 time upper limit normal . Untreated AML , regardless prognostic feature . Treatment chemotherapy biologic therapy within 3 week 225Ac HuM195 administration . Hydroxyurea permit must discontinue prior treatment study . Patients must recover effect previous treatment . Treatment radiation therapy within 6 week 225AcHuM195 administration . Patients must recover effect previous treatment . Active serious infection control antibiotic . Pregnant woman woman breastfeed . Concurrent active malignancy require therapy . Clinically significant cardiac disease ( NY Heart Association Class III IV ) pulmonary disease . Patients HLAcompatible donor bone marrow immediate candidate bone marrow transplantation . Patients candidate alternative treatment know effectiveness . Patients eligible protocol high priority . Patients previously treat monoclonal antibody reason . Active CNS leukemia Other serious lifethreatening condition deem unacceptable principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>MAB HUM 195 ACTINIUM-225 LABELED</keyword>
	<keyword>HEMATOPOIETIC SYSTEM</keyword>
	<keyword>02-017</keyword>
</DOC>